Cited by 32Treatment of Major DepressionElectroconvulsive Therapy StudiesBipolar Disorder and Treatment

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Withdrawal and Rebound Symptoms Associated With Abrupt Discontinuation of Venlafaxine

Dallal, Abdallah, Chouinard, Guy·1998·Journal of Clinical Psychopharmacology

Abstract

Dallal, Abdallah MD, MSc, FRCP(C); Chouinard, Guy MD, MSc (Pharmacol), FRCP(C), FAPA Author Information

Overview

Integrity signals

Registry

Crossref · 10.1097/00004714-199808000-00017

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Clinical case reports described new withdrawal symptoms (panic, anxiety, restlessness, irritability, hypomania, insomnia, dizziness, paresthesia, nausea, vomiting) and rebound mania after decrease or discontinuation of mirtazapine.

    “Among noradrenergic and specific serotonergic antidepressants (i.e., mirtazapine, mianserin, setiptiline), clinical case reports described new withdrawal symptoms (i.e., panic, anxiety, restlessness, irritability, hypomania, insomnia, dizziness, paresthesia, nausea, vomiting) and rebound mania after decrease or discontinuation of mirtazapine [102].”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Lejoyeux, 1996, Drug Ther, 5, 278
  2. Louie, 1996, Am J Psychiatry, 153, 1652

Cited by

Sorted by citations

Metadata

Authors
Dallal, A., & Chouinard, G.
Affiliations
Hôpital de Saint-Jérôme (CA)
Venue
Journal of Clinical Psychopharmacology
Published
1998-08
Volume
18
Issue
4
Pages
343-344
ISSN
0271-0749 (ISSN-L)
OpenAlex
W2092967638
Cited by
32
References
4
Citations by year
2025: 2 · 2024: 1 · 2020: 1 · 2019: 2 · 2018: 1 · 2016: 2 · 2015: 1 · 2013: 2
FWCI
1.72
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
venlafaxine, drug discontinuation, withdrawal symptoms, antidepressant discontinuation, selective serotonin reuptake inhibitors
MeSH terms
Venlafaxine Hydrochloride, Anxiety Disorders, Cyclohexanols, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Recurrence, Substance Withdrawal Syndrome, Treatment Outcome, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review